Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products

Executive Summary

Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market

You may also be interested in...

Novartis MS Therapy FTY720 Enters Phase III With Lower, Untested Dose

Following delays due to FDA safety concerns, Novartis is moving forward with Phase III trials of its oral multiple sclerosis therapy FTY720, although one of the two doses being evaluated lacks clinical data to support its efficacy

Amgen To Re-Launch AMG 706 Phase II Enrollment, Phase III Still Delayed

Amgen will re-launch enrollment of head-to-head Phase II studies for its oncologic AMG 706 after concerns were raised about the potential development of cholecystitis, although the Phase III trials remain indefinitely delayed

Amgen Struggles To Spark Enbrel Growth, Faces Increased Competition

Amgen's strategies for reviving growth in Enbrel (etanercept) are not producing the anticipated results, as the TNF inhibitor has delivered lackluster sales for several consecutive quarters

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts